Effect of Metronomic Chemotherapy on Feline Mammary Adenocarcinoma at Clinical Stage Ⅲ in Three Cases

Abstract

We administered metronomic chemotherapy containing cyclophosphamide as adjuvant chemotherapy for feline mammary adenocarcinoma at clinical stage Ⅲ in three cases. The survival times in the three patients were 271days, 814 days and 261 days respectively. These survival times were longer than those following surgical monotherapy in stage Ⅲ cases. In all cases, patients' quality of life was maintained well without adverse effects. Our protocol may be a possible choice of adjuvant chemotherapy for feline mammary adenocarcinoma, although we must accumulate more cases to validate this.